The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...
Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...
GlobalData on MSN7d
Novartis signs agreement to acquire Anthos for $925m upfrontNovartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...
Swiss pharmaceutical company Novartis (SIX:NOVN) announced on Tuesday that it has entered into an agreement to purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback